July 2026 in “Frontiers in Immunology” In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.
5 citations
,
January 2018 in “PubMed” In this study, applying a biodegradable microneedle patch after topical steroid application significantly increased steroid penetration and improved treatment outcomes in patients with prurigo nodularis compared to the control.
101 citations
,
July 2020 in “Dermatologic therapy” This systematic review reports that "COVID toes" and other skin manifestations can be initial signs of COVID-19, and advises immunosuppressive therapy adjustments only for infected or at-risk patients.
September 2022 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica” This review discusses mucocutaneous manifestations associated with Covid-19, classifies the lesions, and describes their characteristics and treatments but reports no new clinical findings.
October 2025 in “Dermatology and Therapy” This study reviewed the literature on atopic dermatitis and found a strong connection with several other skin conditions, such as psoriasis and alopecia areata, while highlighting potential treatments like JAK inhibitors and dupilumab that show promise for these comorbidities.